nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.08.2010 | Original Paper

Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients

verfasst von: Zhu-Lin Pan, Xing-Ying Ji, Yan-Min Shi, Ji Zhou, Ellen He, Sven Skog

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 8/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

This study was performed to examine possible use of thymidine kinase 1 concentration in serum (STK1) for prognosis of non-Hodgkin’s lymphoma patients following chemotherapy treatment.

Methods

The STK1 levels of 37 patients were determined by enhanced chemiluminescent dot-blot assay on the day before chemotherapy, and on day 1 and day 28 after start of the treatment. The specificity and sensitivity was evaluated by Western blot with anti-TK1 IgY antibody and by receiver operating characteristic (ROC) analysis.

Results

Western blot and ROC analysis of TK1 in serum showed high specificity and sensitivity. The mean STK1 level of the non-Hodgkin’s lymphoma patients was significantly higher compared to healthy persons (p < 0.001). The mean STK1 level increased significantly (p < 0.001) on day 1 and then declined, reaching on day 28 values corresponding to those of healthy persons. The mean STK1 values before treatment and at 1 and 28 days after start of the treatment also correlated significantly with the clinical response (CR, PR and NR) and five-year survival.

Conclusion

Although the number of patients was limited in this study, TK1 in serum might possess an important reference value in the evaluation of treatment and prognosis of non-Hodgkin’s lymphoma following chemotherapy.

Ferguson RE, Carroll HP, Harris E, Maher ER, Selby PJ, Banks RE (2005) Housekeeping proteins: a preliminary study illustrating some limitations as useful references in protein expression studies. Proteomics 5:566–577CrossRefPubMed

Gronowitz JS, Hagberg H, Kallander CFR, Simonsson B (1983) The use of serum deoxythymidine kinase as a prognostic marker and in the monitoring of patients with non-Hodgkin’s lymphoma. Br J Cancer 47:487–495PubMed

He Q, Wang N, Skog S, Eriksson S, Tribukait B (1996) Characterization of a peptide antibody against a C-terminal part of human and mouse cytosolic thymidine kinase, which is a marker for cell proliferation. Eur J Cell Biol 70:117–124PubMed

He E, Mao Y, Wu J et al (2004) Cytosolic thymidine kinase is a specific histopathologic tumour marker for breast carcinomas. Int J Oncol 25:945–953PubMed

He Q, Zhang P, Zou L et al (2005) Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumours than its activity. Oncol Rep 14:1013–1019PubMed

HengZhi C, Zhou H, Tian NB, He E, Skog S (2008) Serological thymidine kinase 1 (STK1) indicates an elevated risk for development of malignant tumors. Anticancer Res 28:3897–3908

Kauffman MG, Kelly TJ (1991) Cell cycle regulation of thymidine kinase: residues near the carboxyl terminus are essential for the specific degradation of the enzyme at mitosis. Mol Cell Biol 11:2538–2546PubMed

Ke PY, Chang CF (2004) Mitotic degradation of human thymidine kinase 1 is dependent on the anaphase-promoting complex/cyclosome-CDH1-mediated pathway. Mol Cell Biol 24:514–526CrossRefPubMed

Kok M, Bonfrer JM, Korse CM, de Jong D, Kersten MJ (2003) Serum soluble CD27, but not thymidine kinase, is an independent prognostic factor for outcome in indolent non-Hodgkin’s lymphoma. Tumour Biol 24:53–60CrossRefPubMed

Poley S, Stieber P, Nussler V et al (1997) Serum thymidine kinase in non-Hodgkin lymphomas with special regard to multiple myeloma. Anticancer Res 17:3025–3029PubMed

Rehn S, Glimelius B, Sundstrom CA (1991) Comparative study of proliferation-associated parameters in B-cell non-Hodgkin’s lymphoma. Hematol Oncol 9:287–298CrossRefPubMed

Sadamori N, Ichiba M, Mine M et al (1995) Clinical significance of serum thymidine kinase in adult T-cell leukaemia and acute myeloid leukaemia. Br J Haematol 90:100–105CrossRefPubMed

Suki S, Swan F, Tucker S et al (1995) Risk classification for large cell lymphoma using lactate dehydrogenase, beta-2 microglobulin, and thymidine kinase. Leuk Lymph 18:87–92CrossRef

Topolcan O, Lubos Holubec L (2008) The role of thymidine kinase in cancer diseases. Expert Opin Med Diagn 2:129–140CrossRef

Törnevik Y, Ullman BJ, Balzarini J et al (1995) Cytotoxicity of 3′-azido-3′-deoxythymidine correlates with 3′-azidothymidine-5′-monophosphate (AZTMP) levels, whereas anti-human Immunodeficiency virus (HIV) activity correlates with 3′-azidothymidine 5′-triphosphate (AZTTP) levels in cultured CEM T-lymphoblastoid cells. Biochem Pharmacol 49:829–837CrossRefPubMed

Wu CJ, Yang RJ, Zhou J et al (2003) Production and characterisation of a novel chicken IgY antibody raised against C-terminal peptide from human thymidine kinase 1. J Immunol Methods 277:157–169CrossRefPubMed

Xu XH, Zhang YM, Shu XH et al (2008) Serological thymidine kinase 1 reflects progression of pre-malignant and malignant tumours during therapy. Mol Med Rep 1:705–711

Zhang ZN, Shen D (1998) Diagnosis of blood disease and response criteria. The second version. Beijing Science Press, Beijing, pp 168–349

Zhang F, Li H, Pendleton AR et al (2001) Thymidine kinase 1 immunoassay: a potential marker for breast cancer. Cancer Detect Prev 25:8–15PubMed

Zhang J, Jia Q, Zou S et al (2006) Thymidine kinase 1: a proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep 15:455–461PubMed

Zou L, Zhang PG, Zou S, Li Y, He Q (2002) The half-life of cytosolic thymidine kinase in serum by ECL dot bolt: a potential marker for monitoring the response to surgery of patients with gastric cancer. Int J Biol Marker 17:135–140

Titel: Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients
verfasst von: Zhu-Lin Pan
Xing-Ying Ji
Yan-Min Shi
Ji Zhou
Ellen He
Sven Skog
Publikationsdatum: 01.08.2010
Verlag: Springer-Verlag
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 8/2010
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-010-0769-z

Neu im Fachgebiet Onkologie

24.04.2024 | DGIM 2024 | Nachrichten

Springer Medizin

Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin’s lymphoma patients

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2010

Epigenetic silencing of WIF-1 in hepatocellular carcinomas

Identification of aberrant promoter hypomethylation of HOXA10 in ovarian cancer

Identification of HTA as a novel-specific marker for human hepatocellular carcinoma

BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer

Detection and identification of potential biomarkers of breast cancer

(−)-Epigallocatechin-3-gallate induces apoptosis and suppresses proliferation by inhibiting the human Indian Hedgehog pathway in human chondrosarcoma cells

Neu im Fachgebiet Onkologie

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Krebspatienten impfen: Was? Wen? Und wann nicht?

Müde im Alter? Auch an die Nebenniere denken

Update Onkologie